Gainers
- Geron GERN stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion.
- Madrigal Pharmaceuticals MDGL stock rose 23.16% to $300.0. The market value of their outstanding shares is at $5.9 billion.
- DIH Holding US DHAI shares rose 10.37% to $1.17. The company's market cap stands at $47.4 million.
- Synaptogenix SNPX stock increased by 8.33% to $0.2. The company's market cap stands at $3.9 million.
- Revelation Biosciences REVB shares increased by 8.05% to $2.55. The market value of their outstanding shares is at $1.0 million.
- Akebia Therapeutics AKBA stock rose 8.02% to $1.48. The market value of their outstanding shares is at $278.7 million. As per the news, the Q4 earnings report came out today.
Losers
- Kineta KA stock declined by 8.3% to $0.56 during Thursday's after-market session. The market value of their outstanding shares is at $5.8 million.
- Trxade Health MEDS shares decreased by 7.38% to $27.0. The market value of their outstanding shares is at $32.5 million.
- Pieris Pharmaceuticals PIRS stock declined by 6.83% to $0.16. The market value of their outstanding shares is at $15.9 million.
- Coeptis Therapeutics COEP stock decreased by 6.42% to $0.35. The company's market cap stands at $11.9 million.
- Nexalin Technology NXL shares declined by 6.28% to $0.51. The market value of their outstanding shares is at $3.6 million.
- Renovaro RENB stock declined by 6.08% to $2.94. The market value of their outstanding shares is at $422.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
COEPCoeptis Therapeutics Holdings Inc
$0.14701.73%
DHAIDIH Holding US Inc
$1.16-10.1%
GERNGeron Corp
$3.52-3.83%
MDGLMadrigal Pharmaceuticals Inc
$308.445.12%
NXLNexalin Technology Inc
$2.75-10.1%
PIRS
$13.26-2.50%
RENBRenovaro Inc
$1.635.50%
REVBRevelation Biosciences Inc
$0.3100-1.46%
SNPXSynaptogenix Inc
$2.55-0.58%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in